Accuray Inc (ARAY)

[surf1944]

Accuray Incorporated to Host Investor Meeting at ASTRO 2012
PR NewswirePress Release: Accuray Incorporated – Mon, Oct 1, 2012 8:30 AM EDT

SUNNYVALE, Calif., Oct. 1, 2012 /PRNewswire/ -- Accuray Incorporated (ARAY), the premier radiation oncology company, announced today that it will host an investor meeting on Monday, October 29, 2012 at the annual meeting of the American Society for Radiation Oncology (ASTRO) being held in Boston. The meeting is open to institutional investors and research analysts.

Accuray's management will host a breakfast meeting, from 7:30 a.m. to 9:30 a.m. E.D.T. on Monday, October 29 at the Renaissance Boston Waterfront Hotel, 606 Congress Street Boston, in the Pacific Ballroom, Salon A-C. The presentation will provide a review of Accuray's new technology platforms that will be introduced at ASTRO. Investors who are attending the trade show are encouraged to visit the Accuray booth #7101.

Attendees are asked to register no later than Friday, October 19 from our event website: http://www.cvent.com/d/bcqxrm.

A live webcast of the presentation will be available online from the investor relations section of the company website at www.accuray.com/investors. The webcast replay of the presentation will begin approximately one hour after the conclusion of the live presentation and will be available for approximately 30 days.

About Accuray
Accuray Incorporated (ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, 642 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.

Available Topic Expert: For information on the listed expert, click appropriate link.
Euan Thomson, Ph.D.
ProfNet - https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869

[surf1944]

8:31AM Accuray signed a definitive agreement to acquire Morphormics, (ARAY) 6.58 : Co announced that they have signed a definitive agreement to acquire Morphormics, Inc., a privately held company founded by University of North Carolina at Chapel Hill faculty members based on their research in autosegmentation of medical images. Morphormics develops medical imaging software systems that automatically recognize and extract anatomical structures from medical images. The agreement provides that Accuray will pay approximately $5.7 million.

[mlkrborn]

Accuray announced it is on track to meet or exceed integration success metrics and expecting near-term return to profitability (ARAY) 5.97 : As part of Accuray's transformative acquisition of TomoTherapy Incorporated on June 10, 2011, the co set forth success metrics. In addition to reiterating the co's plans to return to profitability by the end of fiscal year 2013, which ends June 30, 2013, Accuray provided additional milestones for its fiscal year 2013. These included enhanced revenue growth, beyond the maintained or modestly increased revenue the co committed to for fiscal 2012. Specific guidance for fiscal year 2013 will be announced during Accuray's earnings call for the results for 4th quarter of fiscal 2012, but the co intends to focus on maximizing product sales through continued product innovation and market penetration. Co also anticipates further service gross margin improvements reaching 20-22 percent for the full fiscal year 2013, which is higher than originally announced.

[surf1944]

8:49AM On The Wires (WIRES) :Accuray (ARAY) announced the extension of Emerald Service Program for the TomoTherapy System. Co will now interact directly with TomoTherapy customers in Japan

[mlkrborn]

Serious: german Cancer research Institute took ARAY seriously!

[surf1944]

8:56AM On The Wires (WIRES) :Accuray (ARAY) announced the signing of a multi-year master research and collaboration agreement with the German Cancer Research Center. Accuray and DKFZ will collaborate on research in radiation oncology to advance treatment technology and provide health care professionals with the most effective tools for treating patients.

[surf1944]

8:50AM On The Wires (WIRES) : Accuray (ARAY) announced the launch of the Prostate Advances in Comparative Evidence Study to compare CyberKnife Stereotactic Body Radiation Therapy, da Vinci assisted and manual laparoscopic surgery and conventionally fractionated intensity modulated radiation therapy, for the treatment of localized prostate cancer.

[surf1944]

5:55AM On The Wires (WIRES) : Accuray (ARAY) announced the signing of a multi-year master research and collaboration agreement with the University of Heidelberg, a luminary research institution located in Heidelberg, Germany that contributes to the city's top international position in therapy, research and science.

[grantg2]

Stock is back to 7+... about time for ET's HOG mgmt to NOSE DEEP into the ARAY TROUGH and begin to feed until the PPS is back to 4!

http://www.thejudgingconnection.com/pdfs/Swine_Breeds.pdf

In my imaginings, ARAY's THOMSON HOGS strongly resemble ol' Chester White chowing down!

[surf1944]

Avg Vol (3 month)3: 304,165
Avg Vol (10 day)3: 253,612
Shares Outstanding5: 58.41M
Float: 40.94M
% Held by Insiders1: 20.44%
% Held by Institutions1: 54.80%
Shares Short (as of Jan 13, 2012)3: 2.24M
Short Ratio (as of Jan 13, 2012)3: 7.80
Short % of Float (as of Jan 13, 2012)3: 4.20%
Shares Short (prior month)3: 2.21M

shorts driving ARAY up....

[grantg2]

Does ANYONE really care so long as the GREEDY EUAN THOMSON HOGS MGMT TEAM keeps stealing ALL the PROFITS every quarter...

so shareholders see NO GAIN IN VALUE for YEARS?

[mlkrborn]

ARAY $4.18
Accuray (ARAY) announced today that 23 medical centers have installed both a CyberKnife Robotic Radiosurgery System and a TomoTherapy System.

[surf1944]

http://quotes.barrons.com/aray/ownership

[Penny Roger$]

$ARAY related news.Growing Safety Concerns Weigh on Medical Equipment and Supplies Sector

http://finance.yahoo.com/news/Growing-Safety-Concerns-Weigh-iw-816180413.html?x=0

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68281577

[grantg2]

You've got a handle on the ARAY management skim-off-scam of shareholder value!

[huntermund]

Ok been reading up on Accuray so I wanted to see what you meant by your comment. There is a lot of exercise of options done lately (9/15, 8/24...) than sales by the same two guys. So if I am understanding this, the exercise of options is aquiring shares from the company at the low price, .75 to 2.50, than sales back to the market at lets say 4 to 5 bucks? Or am I totally off here? Thanks in advance.

[huntermund]

Hmm ya Im new to Accuray just caught it on a screener so was interested whats going on here after the 16% drop yesterday.

[Bruce A Thompson]

Looks like it is just another insider

Feeding from the shareholder trough.

[huntermund]

surf are you invested here? if so what do you think with the drop today, overeaction?

[surf1944]

Array BioPharma to Present at the Stifel Nicolaus Healthcare Conference and the Rodman & Renshaw Global Investment Conference

Press Release Source: Array BioPharma Inc. On Monday August 29, 2011, 6:01 pm EDT

BOULDER, Colo.--(BUSINESS WIRE)-- Array BioPharma Inc. (Nasdaq:ARRY - News) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the Stifel Nicolaus Healthcare Conference and the Rodman & Renshaw Global Investment Conference. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website.


Event:
Stifel Nicolaus Healthcare Conference
Presenter:
Robert E. Conway, Chief Executive Officer, Array BioPharma
Date:

Thursday, September 8, 2011
Time:
11:30 a.m. Eastern Time
Location:
Four Seasons, Boston, MA
Webcast:

www.arraybiopharma.com

Event:
Rodman & Renshaw Global Investment Conference
Presenter:
Robert E. Conway, Chief Executive Officer, Array BioPharma
Date:
Monday, September 12, 2011
Time:
10:50 a.m. Eastern Time
Location:
The Waldorf=Astoria, New York, NY
Webcast:

www.arraybiopharma.com


http://finance.yahoo.com/news/Array-BioPharma-to-Present-at-bw-2322579999.html?x=0&.v=2

[surf1944]

8:31AM Accuray announced new clinical data highlighting the ability of its CyberKnife Robotic Radiosurgery System and its TomoTherapy Radiation Therapy System to treat a wide range of patients with lung cancer and lung metastases (ARAY) 8.26 : Co announced new clinical data highlighting the ability of its CyberKnife Robotic Radiosurgery System and its TomoTherapy Radiation Therapy System to treat a wide range of patients with lung cancer and lung metastases. The new outcome data was presented at the 14th World Conference on Lung Cancer, the leading global forum for lung cancer and thoracic oncology research and practice.

[plfminthemiddle]

such a great product what a shame it can't get better as investment goes.

[grantg2]

ARAY slide back down continues

under the skilled leadership and astute decisions of CEO Euan Thomson and his team!

[plfminthemiddle]

Grant I too feel it was a mistake and killed some future profits and killed the stocks good run upwards .
I was excited bout aray until this.
my concerns are still there now.

[mlkrborn]

TomoTherapy, James River: Small-Cap Winners
By Shanthi Bharatwaj 03/07/11 - 01:50 PM EST


Stock quotes in this article:TOMO, JRCC, VRUS, LEI, AVL, REE, GPL

NEW YORK (TheStreet) -- TomoTherapy(TOMO) was leading the gains among small-cap stocks Monday afternoon, after Accuray(ARAY_) said it will buy the radiation firm for $277 million in cash and stock.
More on Small Caps


, a 31% premium to its previous closing price. TomoTherapy shareholders would receive $3.15 in cash and 0.1648 shares of Accuray common stock for each TomoTherapy share they hold.

Shares were soaring 24% to $4.56. Volumes jumped to 15 million shares.

[grantg2]

IDIOTIC EUAN & his team sink to new low acquiring TOMO...

already well on its way to being USELESS in the RT industry!

[grantg2]

no doubt about that... BLNKF is slow and steady... but seems always BIASED upward!

More importantly, management there is not the greedy thieves found in ARAY mgmt...

that team is willing to prosper WITH shareholders, not instead of shareholders with a "GET MY $$$$ FIRST" attitude like Euan Thompson and his gang of pocket-liners!

[plfminthemiddle]

one day grant blinkx will be ten too!

[grantg2]

Still pinching myself every morning that ARAY

HOLDS above 10! LOL

[grantg2]

I'm having a hard time adjusting to the fact that

GREEDY ARAY MGMT did not STEAL all the profits yet again!

As much as ARAY has increased in the last few weeks, I have to wonder where the ARAY PPS would be if EUAN's PIG PARTY had ended many quarters back!

Hey, EUAN... ya greedy SOB... am I dreaming? Will the ARAY shareholder rip-off crank back up next quarter? Perhaps, if you are now a REFORMED PIG TROUGH GOURMAND, you ought to issue a statement declaring the new era at ARAY where all of the quarterly profits will NOT be stolen every 3 months!

[grantg2]

plfm... I've heard of them... but have not looked too closely at their pipeline, etc.

The time waiting can be very IFFY for pharmas... CBST was one that ran to 40 on speculation of a wonder antibiotic "soon" to be approved... has taken forever to establish a market. Now its only in the low 20s last I looked some months ago... but it was/is(?) only a one-drug company.

I'll check into GERN... always better IF they have a number of products in the pipeline being developed and tested.

As for ARAY... maybe the company has reached a point of critical mass for its growth into the future. So many reasons that it ought to prove superior to other modalities for any given treatment protocol. And cheaper overall for insurors! I'd expect private insurors to realize this & PUSH for adoption of CK... but the gub-ment is a dinosaur, brain the size of a peach right above its behind!

Unfortunately, looks like FDA approval will be the KEY to approval for insurance reimbursements easing. ARAY should move higher with each cancer protocol that gets approval! At least we have a start with lung cancer.

I have NOT checked recently into the share structure of ARAY compared to ISRG... clearly IMO ARAY mgmt is INFERIOR to ISRG mgmt... but ISRG has finally become credible enough to maintain its PPS above 200 even through the recent bad market.

I'm hopeful that one day ARAY will get above 100 to stay! Although it may have a few more growing pain years to overcome.

[plfminthemiddle]

grant this is great news and a great run but I paid over ten for each of my shares long ago.
grant a article on GERN on the other day said that if he could only on one stock long term it would be GERN heard of them ?
GERN has hesc tons of patents and first human trials for spinal cord injury .
Huge cancer drug pipeline .
the downfall of them is its gonna take along time to get trails done along time but its cheap now if you can wait that long..

[mlkrborn]

Accuray records 2Q profit, shares jump; over $9.00 almost 52 weeks high level on earnings report!
Accuray records unexpected 2nd-quarter profit on lower costs, shares surge
ap



Related Quotes
Symbol Price Change
ARAY 9.24 +2.38
\
On Friday January 28, 2011, 1:12 pm EST

SUNNYVALE, Calif. (AP) -- Medical radiation equipment maker Accuray Inc. on Friday recorded a fiscal 2011 second-quarter profit on lower costs and reported a strong backlog of orders.

The profit was not expected by Wall Street and shares of Accuray rose $1.98, or 29 percent, to $8.84 in afternoon trading. The stock earlier reached a 52-week high of $8.95.

Accuray makes the CyberKnife Robotic Radiosurgery System, which it describes as the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively.

It said its total backlog of orders for systems and services rose 26 percent to $410 million at the end of the latest quarter from the year-ago period.

The company earned just under $4.1 million, or 7 cents per share, compared with a loss of $1.2 million, or 2 cents per share, during the same period a year prior. Revenue fell 5 percent to $54.2 million from $57.3 million. The quarter ended on Dec. 31.

[grantg2]

IT'S ABOUT TIME!!!!!!!! Up 2+ (30+%)

on good earnings!

Now we have to HOPE EUAN-THE-HOG and his greedy management PIGS don't belly up to the feed trough and HOG all the earnings ONE MORE TIME!

Which would be them just doing BUSINESS as usual (on the shareholders)!

[plfminthemiddle]

grant thanks for such an informative post as you always do it makes me feel better that you still have high hopes for ARAY as we have held it seems like forever. Also still glad you are holding blinkx as they are well on their way to getting into IPTV and smart phones and still growing the web site without a globial push yet .
I can't help but to wonder why blinkx recently raised 26 million dollars they now have 40 million in cash no debt I am lookin for blinkx to be buying another company out IMO and possibly one on the nasdaq as some small caps are still very cheap .
I also would like you to look at IDCC i know they are almost fifty but they simply own 17,000 patents for cell phones which they have 50% of 3 G cell phones pays them fees if they get nokia then make that 75% some say they are on nokias heels alot of people shorting idcc bc of nokia lawsuit if idcc wins shorts will be buying it up fast to cover and it is said rumored if you will to be up to 500 million dollars plus intrest if they don't settle outta court .
I will look at your LNGT. thanks for the heads up on that one.
I am very limited for funds as my hours at work have been cut.
But that gives me more time to chat with you..
haha Now lets make some money fast and lots of it!!

[grantg2]

plfm... IMO ARAY's management ought to face a firing squad for stealing from shareholders!

In the recent years a drama has unfolded that I find to be very curious... and the management of ARAY might have screwed themselves by their practices that have kept the stock price so stagnant at 6-8.

First, Dr. ADLER (the inventor of CK) left ARAY in a dispute with management... he himself said little publicly, but his wife said enough that it was obviously NOT a friendly split. After an interim period, it appears that Dr. Adler has landed at Varian in some capacity.

Perhaps he will coinvince VARIAN to BUY ARAY.

Varian has the money to do so & if they finally are ready to admit that CK IS SUPERIOR to their radiation sprayers that are less beneficial (IF NOT outright harmful to patients IMO) in treating cancer.

Recent FDA approval for lung cancer and the release of the prostate data with treatment/cure results equal to or better than other modalities... and minimal negative side effects... means that ARAY is very close to achieving full legitimacy for its cancer treatment protocols! This is going to be a terrible blow to the other competitive(?) treatment choices because CK is so much more cost effective without the invasive trauma of surgeries!

Yes... I still own ARAY shares and hope to see CK become so successful that ARAY is a valuable HOLD in my portfolio... might even reach the 50-100 that I'd originally hoped it would do years ago when I found it dropping downward from the IPO frenzy.

ISRG took a long time before it reached this pinnalce that it enjoys... it has been some time since its last retreats back to the low 100s. Those low swings are likely a thing of the past... but it just seems to hover from high 200s to mid-300s. Don't know if ISRG has much of a dividend, but growth and price appreciation seem to have settled into the PPS into a trading range. IOW ISRG is possibly (with little or no dividend) a cash cow stock that can now be bought when it drops into the 200s and sold on the runs into the 300s. JMO on ISRG of course, but it is how I've played it lately. I do run the risk that it will surge way away from me during the time I do not hold it.

Finally... YES I am still holding BLNKF (thanks to you... should have listened a lot earlier than I did) and expect it to be worth HOLDING for a long time to come... I'll be adding more whenever I can if there isn't something more compelling.

FWIW... this past week LNGT announced sales of its DazerLaser to Lehigh Valley Healthcare Network. Medical facility security is woefully disregarded and often inadequate. DL is cost effective & gives hospital security a very effective violence control device that minimizes the dangers that could be encountered there. I am surprised that this sale happened well before any border security or military sales.

Palm Bay (FL) PD became the first announced buyer of DL when it bought 5 DLs a few weeks ago for field trial and tactics development. Of interest is that PBPD also was the first buyer of TASER when it first went to market. (General Dynamics assisted TASR bringing product to markets.)

General Dynamics has been displaying LNGT's DazerLaser in its booths at trade shows for almost a year now... & GD's ATP facility in Charlotte, NC, will be manufacturing DLs (for LNGT) when full commercial production begins. I find this GD linkage between the two products early in their marketing to be compelling and fascinating!

Oh, BTW, TASR was trading at .38 when GD came along to give it a boost into markets with GD sponsorship... 18 months later TASR was in the mid-20s. Compelling & fascinating!

[plfminthemiddle]

grant ISRG reported huge profits while ARAY which has a great robot for cancer can't seem to get the ball rolling in the right direction what gives is it the mgnt of the company being greedy ?
Also do you still hold shares of ARAY .
Also hope you still have some blinkx stock too.

[mlkrborn]

Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market Lung Optimized Treatment, a new component of the CyberKnife® VSI™ System. The 510(k) clearance enables Accuray to provide physicians with greater flexibility in delivering radiosurgery treatments to patients with lung cancer, the most common and deadly cancer worldwide.

Recent studies have found radiosurgery to be an effective treatment option for medically inoperable lung cancer patients as it provides good local control and survival rates. Treating these tumors is particularly complex due to movement with respiration and nearby critical structures. This is especially the case for central and chest wall tumors, which are located in close proximity to such critical anatomical structures.

Lung Optimized Treatment offers the accuracy and steep dose fall off required to safely treat lung tumors, even those close to such critical structures. Simulation and comparison workflows, combined with unique tracking modes, allow the clinician to select from multiple, non-invasive options, providing lung SBRT patients
the optimal non-invasive treatment option, regardless of tumor location.

"Lung Optimized Treatment is a new tool we developed to meet the clinical demand for more flexibility in treating lung cancer patients with radiosurgery and the desire to move away from reliance on fiducial markers," said Chris A. Raanes, senior vice president and chief operating officer for Accuray. "This new technology
enables treatments throughout the lung without a single incision, all while safeguarding healthy tissue and structures around the tumor to ensure they are not damaged by radiation."

Because fiducial implantation is no longer required, CyberKnife radiosurgery with Lung Optimized Treatment offers a completely non-invasive option, which is particularly important for medically or surgically inoperable patients. This means patients who are not candidates for fiducial placement or physicians who choose not to implant fiducials due to the high risk of pneumothorax, now have a non-invasive alternative using the CyberKnife System's unique tracking and correction capabilities.

"With the FDA 510(k) clearance of Lung Optimized Treatment, we've taken the CyberKnife technology to new heights and enabled care for an expanded group of patients," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray. "This is yet another step in our efforts to ensure physicians have access to the treatment choices necessary for their patient, based on the patient's specific needs. To this end, Accuray continues to investigate ways to improve patient care across various indications."

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 100,000 patients worldwide and currently more than 215 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

[mlkrborn]

Nice jump over $6.00 with FDA clearence:
http://ih.advfn.com/p.php?pid=nmona&article=45663798

[grantg2]

I am still holding ARAY... but only about HALF as many as when I first got hooked by the technology.

Once I realized that mgmt was given to falsely deceiving shareholders while looting earnings every quarter, I resolved to trade it to lower my basis in ARAY.

I loved the drop to 12 back when: sold some shares at 17, bought at the drop 12+, and rode the run back to about 16 & bailed on HALF... it evened out most of my "hostage dollars" that ARAY had taken away from me when I bailed out of half my holdings after that buy-in around 12 and selling at the top of that run.

It got harder FOR ME to play the moves once it got down in the 5-7 range. I did one more trade cycle just below 7 and sold out those shares close to 8. I've been holding my core position ever since. I just could NOT convince myself to BUY ARAY again when it was under 5. Would have been a modest little gain again.

I really must get better at TA so I can play based on charts with some degree of confidence. (MY) Charting stocks is way more unreliable than charting commodities IMO.

I'm very surprised ARAY is still single digit... however, I am resolved that IF I ever have a cancer CK can treat, CyberKnife will be my choice. In fact, I almost made out a Healthcare POA to that effect... but my attorney convinced me to hold off on that so long as my spouse and I are of sound mind... LOL... that is an uncertain time span for sure!

I have not looked at any of the other plays you mentioned in your post...

however, blinkx convinces me I should take a close look over the weekend and get back to you. Too bad for me I did not sell HALF my ARAY and BUY blnkf at .30+ back then 2 years ago.

I did finally buy some... not enough to brag about and it was just above .50 which is NOT the gain I could have had IF I'd listened to you earlier on... still about 2x is not bad.

Last I knew, though, being up 4x was better than 2x! and BOTH beat ARAY over the last 2 years!

[plfminthemiddle]

are you into limelight ?
thats a huge field i was looking at them yesturday with the run up AKAM how are they different ?
Also looking at VHC.
VHC has 46 patents and has won a 120 million lawsuit with microsoft for infinge and microsoft not only paid but licenced with them after that and now VHC is suing NEC Cisco and Apple.
They have no debt and look good as we turn the corner to 4 g .
I still have blinkx their AGM is today I am excited .did not sell any.

I still have ARAY what a disapointment it has been great tech and no gains from it coz of mgt.
Are you still holding it too?

I think there may be much upside to TINY and WZE and ACAS all of which are trading below book.
let me know if any of them intrest you .
its always good chating with ya I hope all is going good for you in the terrible economy we have

[grantg2]

Hi, plfm...

I think your blinkx is up a LOT since you first mentioned it to me over a year ago & looks like a winner. Quietly it has stuck to its business plan and grown nicely... which may account for why Fool is now picking up on it.

Not bad advice by Fool & no doubt blinkx meets the criteria... BUT you did find it when it was way cheaper. Hopefully you have had the patience to hang with it & even add more along the way up.

Long ago I encountered similar advice about building a Long Ball Portfolio but the advice was to spread out funds in a minimum of 10 stocks (with equal amounts invested}...

more importantly, the advisor said: Be patient with your picks (which you should believe in because you did your DD on them) & give them the time to become what you expect of them...

of course, that is the hard part because no stock (or company) executes perfectly and riding thru the stumbles can be very worrisome with small cap stocks. And some fail to deliver and end up worthless.

The temptation is to "take your loss" or "recover your money" and move on to the winning stock you think was just found. Not a good strategy because you end up with losers and forever chasing a dream that does not materialize. Better to pick carefully, write off the ones that lose... provided... you are learning the lesson well and have a couple of winners! One 10x winner out of the ten stocks is break even and serious money can be made if you can hit 2-3 winners in every set of ten stocks owned.


Over the years, I've learned to follow the advice of 10 stocks (Rule Morph #1... but seldom more than 15 & NEVER more than 20 because it is just too many to follow) & take some profits when one does run hard. I usually use some of the profits to buy a new stock for the spec portfolio & spend the rest. The rules have changed for me a bit over the years since my first 10 picks had about $1K in each pick & not all were bought right away but over time. Now I'm putting significantly more into my initial purchase of a pick (Rule Morph #2 from my initial $1K limit... from 30 years ago). And (Rule Morph #3) I'll add more to a holding IF the stock looks like it is really gonna fly hard... like LNGT is setting up to do! You ought to check out the last 5-6 PR releases on it... Dazer Laser is ready to fly and LNGT is still under a dime! General Dynamics is now the "big brother" looking out for LNGT's shareholders & will git-r-done! When GD first helped Taser along, it ran from .38 to 28 in about 18 months.


Aray is one that severely tries my patience! IMO it should have done better and at least had a run back to IPO levels by now... but mgmt is NOT good at looking out for stockholders' money invested... ARAY should some day succeed in spite of mgmt greed... but it languishes as dormant money. I'm glad I flipped it a few times for profits in the last few years. I'm now holding less of it than I did 3 years ago with less at stake.

GLTY... and I hope this does not get deleted from the board.

[plfminthemiddle]

hi grant
here is a motely fool article mentions blinkx whats you take on it?




To maximise your chances of achieving a 10-bagger in 10 years without throwing trying to hit every single ball for six, focus on smaller companies that have:

* strong balance sheets;
* strong cash flows; and
* strong growth prospects.

One such company could be Blinkx (BLNKF - news) . According to Google Finance, this £170 million company "has an index of over 35 million hours of searchable video and more than 530 media partnerships, including national broadcasters, commercial media giants, and private video libraries".

Analysts at Daniel Stewart recently forecast 2012 revenues at Blinkx of £79.5 million and EPS of 4.5 pence, putting the company on a 2012 P/E of 13.7. This fast growing rising star of the UK internet industry is the type of company that could just turn out to be a 10-bagger in the years ahead...

from Motley Fool (via Yahoo Finance)

---------

Comment: Only a ten-bagger? Don't think so. If Blinxk comes anywhere close to achieving its potential should be much, MUCH more than that...

[mlkrborn]

ARAY still $6,00s stox!

[grantg2]

Might have been a fine investment

if Euan Thomson hasd not F'd it up!

Handwriting on the wall:

Varian Medical Systems (NYSE: VAR) today announced that it has appointed John R. Adler, Jr., M.D., as Vice President and Chief of New Clinical Applications for the company. Dr. Adler, a renowned neurosurgeon, professor of Neurosurgery and Radiation Oncology at Stanford University, and past CEO, chairman and founder of Accuray, Inc., will be joining Varian to play a key role in guiding the development of Varian's next-generation clinical products and applications for radiosurgery and other new treatments.

"John Adler brings a unique combination of strengths to the Varian team, including expertise in radiosurgery together with an impressive record of success as a clinical researcher, innovator, and entrepreneur," said Tim Guertin, president and CEO of Varian. "He is a respected clinician who will have a strong voice in the development of Varian's next-generation surgical products."

"I welcome the opportunity to join Varian where I will have a broad technological platform and management's enthusiastic commitment to continue shaping the still-emerging field of radiosurgery and to enhance clinical offerings for radiotherapy," said Dr. Adler. "Varian is already among the leaders in radiosurgery and I am convinced that the future will bring even better technology and a broadening array of clinical applications for precision radiation that can attack more and more diseases and help save the lives of untold numbers of patients."

Dr. Adler, who joins Varian effective April 5, will report to Guertin and be a member of the CEO staff. He will represent Varian at medical meetings and partner with radiation oncologists and surgeons to develop products and clinical approaches that expand the applications for and improve the outcomes of radiosurgery. His responsibilities include working with the medical community to improve the effectiveness and efficiency of Varian clinical products through best-in-class designs, techniques, and processes.

Varian has installed more than 170 dedicated surgical units and another 1,000 units capable of both radiotherapy and radiosurgery among more than 5,800 installations operating around the world.

Dr. Adler, 55, was the Founder, CEO, Chief Medical Officer, Chairman and Board Member for Accuray (Nasdaq: ARAY), where he served from 1991 until 2009. He also served as a Professor of Neurosurgery and Radiation Oncology at Stanford University from 1987 through 2010. In his most recent position at Stanford, Dr. Adler served as the Dorothy and TK Chan Professor of Neurosurgery. Prior to joining Stanford, Dr. Adler did a neurosurgical residency at the Brigham & Women's, Children's and Massachusetts General Hospitals in Boston. His training included a one year fellowship with Lars Leksell at the Karolinska Institute, the father of radiosurgery.

He serves on the editorial boards of the Neurosurgery, Technology in Cancer Research & Treatment, Journal of Image-Guided Surgery, Chinese Journal of Clinical Oncology,and functions as editor in chief of peerEmed.com. Dr. Adler previously served on the editorial boards of Stroke and Journal of Radiosurgery.

Dr. Adler is currently president-emeritus and chairman of the CyberKnife Society, an organization he founded, and a member of the Congress of Neurological Surgeons, the American Association of Neurological Surgeons, the Western Neurosurgical Society, the John W. Hanbery Society, the International Society of Stereotactic Radiosurgery, and the American Society of Stereotactic and Functional Neurosurgery.

Dr. Adler graduated magna cum laude from Harvard College in 1976 and from Harvard Medical School in 1980.

Note to editors: High resolution photos are available in the Varian online newsroom.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,000 people who are located at manufacturing sites in North America, Europe, and China and approximately 79 sales and support offices around the world. For more information, visit http://www.varian.com. VMS122



FOR INFORMATION CONTACT:
Spencer Sias, [phone]
[e-mail]



SOURCE Varian Medical Systems, Inc.

[grantg2]

JBII... the management ARAY shoulda had!

[DewDiligence]

This is an FYI item—I have no idea is this product competes with anything ARAY is doing:

http://finance.yahoo.com/news/Radiation-Breakthrough-Gives-prnews-3587138924.html?x=0&.v=1

[grantg2]

World's first heart surgery using radiation


Digital Publisher of the Year | Monday 02 November 2009 | Rebecca Smith feed
Log in | Register now
Website of the Telegraph Media Group with breaking news, sport, business, latest UK and world news. Content from the Daily Telegraph and Sunday Telegraph newspapers and video from Telegraph TV. Enhanced by Google
Jobs Dating Games Offers
HOMEJOURNALISTS
REBECCA SMITH
World's first heart surgery using radiation
A British man has become the first person in the world to undergo heart surgery using radiation.

By Rebecca Smith, Medical Editor
Published: 9:00AM GMT 02 Nov 2009
Michael Kilby, 67, was told he may only live until Christmas after doctors found a tumour inside the right chamber of his heart larger than a golf ball. It was so big it was blocking the blood flow and he was dying.
After conventional surgery, radiotherapy and chemotherapy, his last option was to try revolutionary surgery involving highly focused radiation as a 'scalpel' to cut away the tumour inside his beating heart.

Related Articles
Sir Ranulph Fiennes conquers Everest on third attempt
Sir Ranulph Fiennes portrait
Teenager obsessed by World of Warcraft first to attend US internet addiction retreat
World Athletics: Phillips Idowu targets Olympic gold after win in Berlin
Carlo Ancelotti: uncovering the truth about new Chelsea manager
Now just 10 days later he is planning a five month trip to Australia, Indonesia, New Zealand and America with his wife, Licette Gus.
The treatment is the first time the radiation scalpel, called the Cyberknife, has been used in heart surgery and doctors are confident that it could lead to new treatments for other heart conditions.
Radiation beams controlled by a robotic with an accuracy of one millimetre arm attack the tumour. It is able to take account of breathing patterns and body movements to avoid healthy tissue. Pieces of gold were attached to Mr Kilby's heart to act as an extra guide.
Mr Kilby was diagnosed with a rare cancer of the duodenum, part of the small intestine, 10 years ago which was successfully removed.
Then three years ago a secondary cancer was found in his right lung and one third of it was removed.
But then in a third blow, he began suffering severe breathlessness and a scan found a large tumour had formed inside his heart.
Surgeons at the private Harley Street Clinic in London first carried out emergency open heart surgery to try and take out as much as they could, but the tumour had burrowed into the muscle of the heart and it could not all be safely removed.
Conventional radiotherapy and chemotherapy failed and the tumour began to grow again within just six weeks.
When Mr Kilby, a retired businessman from Moreton in Marsh, Glouchestershire, was about to give up and accept his fate, it was suggested he try the Cyberknife.
The technique had never been used on the heart before and because the operation was experimental Mr Kilby's health insurance would not cover it.
After consulting his wife and their three grown up children, he decided to pay the £22,000 required and the course of five treatments began.
The tumour has already shrunk by 40 per cent and is expected to shrink further over the next three to four weeks.
Mr Kilby said: "My options were to give the Cyberknife a go or I was going to die by Christmas. I talked to my wife and the children who said they did not want any inheritance so we went for it.
"I was treated for five days with each session lasting for about an hour and a half. You cannot feel anything at all, its just like radiotherapy.
"Before the Cyberknife I couldn't speak in long sentences because I would get out breath, but now I can walk a few holes of the golf course."
Nick Plowman, clinical oncologist, said: "This was an absolutely unique case. The tumour was taking up so much of the ventricle that the heart was failing in front of us. There was nowhere else to go with his treatment.
"The tumour has shrunk significantly and I expect it to shrink further in the coming weeks. It is great."
Dr John Coltart, consultant cardiologist at the Harley Street Clinic, in London, said: "Three months ago his prognosis was terrible, now he may live for a good while yet. No one had ever done this before, it was a bit of innovative thinking to give this gentleman a chance.
"All our expectations have been realised."
Dr Coltart said tumours inside the heart are extremely rare and it seems that the Cyberknife may now be the preferable way to treat them because the radiation can be targeted to such a degree that there is minimal damage to the heart muscle.
He said such tumours inside the heart are extremely rare, with probably only 40 or 50 found each year in Britain, with few being operable.
Dr Coltart said as well as opening possibilities for other heart tumours to be treated, the Cyberknife could be used in future to treat arrythymia, where the heart beats erratically or fast.
Normally a fine wire is passed into the heart to destroy the tiny piece of heart muscle that is causing the abnormal electrical pulse, but the Cyberknife could also be used to do this in a less invasive procedure, Dr Coltart said.

[grantg2]

Very interesting... Sunday PR release! em

[grantg2]

Just got my proxy for the annual meeting to be held on Nov. 20!

Item # 2 on the proxy statement is a chance to vote "for" of "AGAINST" the Performance Bonus Plan for the PIG TROUGH boys!

Guess how I'm voting!!!!!